久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

AstraZeneca ups R&D localization

By Zheng Yiran | China Daily | Updated: 2018-12-04 11:00
Share
Share - WeChat
A man walks past an AstraZeneca site in Macclesfield, north England. [Photo/Agencies]

Global biopharmaceutical giant AstraZeneca PLC is promoting the research and development of seven medicines in China, as the company endeavors to strengthen its local R&D capabilities to lower costs for patients.

According to the company, it will take advantage of its production and logistics bases in Wuxi and Taizhou in Jiangsu province to mass produce high-quality and low-cost medicines.

"In addition to the Chinese market, we supply over 70 countries around the world, mainly developing countries. We will use our production advantages to raise production and lower costs, so that patients can benefit from more reasonable prices," said Wang Lei, CEO of AstraZeneca China.

At the China International Import Expo, the Cambridge, United Kingdom-headquartered company demonstrated roughly 30 innovative products that it had brought to China since entering the country 25 years ago. A renal anemia medication, which is being developed locally in China, was displayed at the expo. The drug is set to make its global debut in China next year.

According to Wang, AstraZeneca hopes to bring its global experience to China through the CIIE. The company hopes to integrate its experience with China's successful internet of things ecosystem, colliding with more creative sparks, to meet the country's ever-changing and upgrading medical needs and pain points, by bringing new solutions for Chinese patients, he said.

Wang said China has evolved into the company's second-largest market. As the second-largest medical consumption market in the world, China is also the company's fastest-growing market, with 12 percent year-on-year growth in 2017, he said.

Company statistics show sales revenues stood at $22.5 billion in 2017, of which $2.96 billion was from China, 13.2 percent of the total.

That makes AstraZeneca the second-largest multinational pharmaceutical company in China. To date, it has invested more than $750 million into R&D of medicines that improve people's quality of life

Having operated in China for 25 years, the company continuously adjusts its development strategy, and is beginning to place a heavier emphasis on local R&D innovation.

"In the past, we merely brought foreign drugs into China. From now on, we will develop new drugs locally in China, and bring the products not only to Chinese patients, but also patients from other developing countries. China's innovative drug imports and market access are accelerating. This shifts our emphasis onto specific medicines and anti-cancer drugs," Wang said.

For AstraZeneca, R&D localization is an important opportunity for multinational pharmaceutical companies, leading it to promote the R&D process of seven new drugs in China.

The innovative products and development models based in China can also be applied to other markets, says the company.

"The innovative business model in China will not only stay in China. After being applied to various therapeutic fields, the model can be used in other markets. In the future, governments and medical institutions in other countries will rush to embrace Chinese innovation, and that era is coming soon," Wang said.

Yang Wenya, a medical analyst with Beijing-headquartered think tank EO Intelligence, said: "For medical companies, local innovation in developing new medicines takes advantage of the local production advantages to cut costs and raise efficiency, throughout the process of R&D, production and transportation. In this way, both medical companies and patients benefit. This is an inevitable trend of the international division of labor."

She said China's large patient pool offers abundant resources for clinical research and data is easy to access.

"Producing medicine locally saves the cost of transporting medicines. Also, the two major production logistics bases in Wuxi and Taizhou have obvious agglomeration and scale effects, which can guarantee the quality and quantity of drugs," Yang said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 国产一级做a爰片久久毛片男 | 91亚洲精品久久91 | 亚洲国产精品网站久久 | 在线精品欧美日韩 | 国产情侣真实露脸在线最新 | 久久九九视频 | 中文字幕免费 | 国产精品国产三级国产在线观看 | 中文国产成人精品久久水 | 香蕉视频黄色在线观看 | 麻豆国产96在线 | 中国 | 欧美一级淫片免费观看 | 香港台湾经典三级a视频 | 亚洲精品在线网站 | 欧美日本亚洲国产一区二区 | 久久精品成人国产午夜 | 日本一级做人免费视频 | 日韩人成| 国产情侣久久精品 | 久久一日本道色综合久久 | 亚洲综合久久久 | 欧美一级特黄刺激爽大片 | 久久久久久久91精品免费观看 | 欧美国产综合视频 | 成人性视频免费网站 | 欧洲做人爱c欧美 | 性欧美精品 | 久草国产在线 | 黄色影院在线观看视频 | 国产精品久久久 | 国内精品久久久久影院老司 | 久久公开视频 | 北条麻妃在线一区二区 | 美女黄频网站 | 免费网站看v片在线香蕉 | 操12p| 性高湖久久久久久久久 | 成人国产三级在线播放 | 免费的特黄特色大片在线观看 | 国产手机在线国内精品 | 日本三级成人午夜视频网 |